As marijuana purchase becomes easy and legal in U.S states and Canada, so is investing in it. This is why the list of cannabis stocks is getting lengthier. Everybody from celebrities and stars to big companies expresses their interest in cannabis investment and it is a question whether it is worth. In 2018, the Canadian cannabis companies like Cronos Group, Canopy Growth, Aurora Cannabis, Tilray, Aphria and others were the biggest pot stocks to watch on the U.S Exchanges. Companies like CannTrust joined the cannabis stocks in 2019 while U.S companies such as CuraLeaf, Green Thumb, Acreage Holdings and MedMen became public in Canada.
Talking about the ETFs, a cannabis-focused investment option is ETFMG Alternative Harvest ETF. The top 10 holdings of the fund, as in 2019, consist of the above-mentioned U.S listed pot stocks including Hexo that listed on the NYSE America this year. It also tracks companies like GW Pharmaceuticals. According to a recent estimate, U.S Cannabis sale is expected to reach $80 billion by 2030 once it is legalized federally. Legal recreational marijuana sale in Canada could reach $4.34 billion as estimated by Deloitte. Large alcohol brands and other beverage-producers have joined forces with the industry. People from these companies believe people will eventually turn to marijuana to get rid of pain meds and sleep aids.
However, there are few reasons for concern. As the industry attracts increasing cannabis investment, it is unclear when it will ease into more common forms like Apple’s stock chart. An investor alert has been issued with a list of signs of fraud to look for. There are some cannabis companies chewing up investor’s money. Moreover, nobody knows which companies will survive in the current trend and expansion craze. Psychedelics becomes a topic of discussion in much of the US and across Europe. There are psilocybin mushroom-infused lollipops, gummy worms, psychedelic drinks, ‘shroom-infused jello, and more. Magic mushroom Canada is a trusted and authorized vendor that sells genuine product.
The U.S government has not yet legalized cannabis federally. But with the spread of legalization across Canada and U.S, illegal sales are fading away gradually. Huge cultivation facilities and dispensaries have taken their place. People can easily get nasal sprays, marijuana-infused beverages, vapes and gels. As the trend grows further, cannabis companies find cracks in the barrier between the two countries. In 2018, Canadian cannabis companies began buying and selling on U.S Exchanges as medical marijuana is legal where it is based. Canadian cannabis producer Cronos Group was the first cannabis stock to watch on the Nasdaq. Later, Canada-operated Tilray became the first cannabis IPO of Nasdaq.
As in 2019, Aurora Cannabis, CannTrust, Canopy Growth and Aphria are trading on the New York Stock Exchange. Due to the huge investment from Constellation Brands, Canopy Growth will have far more cash than its competitors. A large number of cannabis investment enthusiasts are likely to be retail investors. They are individuals and not institutions. Other marijuana stocks include indirect cannabis sale companies. GW Pharmaceuticals, for example, creates anti-seizure drugs based on marijuana. ETFs such as ETFMG Alternative Harvest ETF also have wider exposure. Larger companies are also interested in a recreational wave across Canada. They keep a watch on the medical market in the country and abroad. Germany is found to be specifically promising in this regard.